ENTRY       D04489                      Drug
NAME        Ibritumomab tiuxetan (USAN/INN);
            Ibritumomab tiuxetan (genetical recombination) (JAN);
            Zevalin (TN)
PRODUCT     ZEVALIN (Acrotech Biopharma)
REMARK      Therapeutic category: 4291 4300
            ATC code: V10XX02
            Product: D04489<JP/US>
EFFICACY    Antineoplastic, Radioactive agent, Anti-CD20 antibody
  DISEASE   Low-grade or follicular non-Hodgkin's lymphoma (CD20-directed) [DS:H00005 H00011 H01613]
  TYPE      Monoclonal antibody
TARGET      CD20 [HSA:931] [KO:K06466]
  PATHWAY   hsa04640(931)  Hematopoietic cell lineage
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             V VARIOUS
              V10 THERAPEUTIC RADIOPHARMACEUTICALS
               V10X OTHER THERAPEUTIC RADIOPHARMACEUTICALS
                V10XX Various therapeutic radiopharmaceuticals
                 V10XX02 Ibritumomab tiuxetan (90Y)
                  D04489  Ibritumomab tiuxetan (USAN/INN) &lt;JP/US&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D04489  Ibritumomab tiuxetan (USAN/INN); Ibritumomab tiuxetan (genetical recombination) (JAN)
              43  Radioactive drugs
               430  Radioactive drugs
                4300  Radioactive drugs
                 D04489  Ibritumomab tiuxetan (USAN/INN); Ibritumomab tiuxetan (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD20
                 D04489  Ibritumomab tiuxetan (USAN/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04489
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D04489
DBLINKS     CAS: 206181-63-7
            PubChem: 47206337
            NIKKAJI: J2.115.705H
///
